COMPANY RESEARCHCombines gene-edited animal-model products and preclinical services with RenMice antibody discovery, licensing/transfers, and collaborative development.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
| Period | Currency / basis | Revenue | Net profit | Operating cash flow | Report |
|---|---|---|---|---|---|
| FY2025 2025-12-31 | CNY PRC Accounting Standards / consolidated | 1,378,808,400 | 173,199,800 Net income attributable to shareholders of the listed company | 370,252,100 | Original ↗ |
| 2026Q3 (YTD) 2026-09-30 | CNY PRC Accounting Standards / consolidated | 1,402,762,040.42 | 312,449,556.18 Net income attributable to shareholders of the listed company | 421,845,263.31 | Original ↗ |
Disease tags match recorded text mentions and require program-level verification.
Combines gene-edited animal-model products and preclinical services with RenMice antibody discovery, licensing/transfers, and collaborative development.
Listed as SSE 688796 / HKEX 02315; original 2025 annual and 2026Q3 (YTD) reports reviewed.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Animal-model products / preclinical CRO / antibody discovery | Not applicable (services/platform) · Drug research and manufacturing services for clients | Services / platform | Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.